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Abstract
Malaria remains the most prevalent and devastating parasitic disease
worldwide. Vaccination is considered to be an approach that will
complement other strategies for prevention and control of the disease
in the future. In the last 10 years, intense studies aimed at the
development of a malaria vaccine have provided important knowledge
of the nature of the host immunological mechanisms of protection and
their respective target antigens. It became well established that protec-
tive immune responses can be generated against the distinct stages of
Plasmodium. However, in general, protective immune responses are
directed at stage-specific antigens. The elucidation of the primary
structure of these antigens made possible the generation of synthetic
and recombinant proteins that are being extensively used in experi-
mental immunizations against the infection. Today, several epitopes
of limited polymorphism have been described and protective immuni-
ty can be generated by immunization with them. These epitopes are
being tested as primary candidates for a subunit vaccine against
malaria. Here we critically review the major roadblocks for the
development of a malaria vaccine and provide some insight on how
these problems are being solved.
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Introduction
Malaria remains the most prevalent and
devastating parasitic disease worldwide, with
a yearly estimate of more than 200 million
cases due to Plasmodium falciparum and at
least 40 million cases due to P. vivax. The
population at risk is estimated at more than 2
billion people living in tropical regions of the
world. The disease is most prevalent in Af-
rica, where children under 5 years of age are
the individual group at higher risk of death
due to infection. Malaria transmission also
occurs in large areas of South Asia, Latin
America, and Oceania. Although the pattern
of disease transmission, infection and mor-
tality in these endemic areas is quite diverse,
malaria has never been a greater problem
than it is today, and it is likely that this
circumstance will not improve worldwide in
the next five to ten years.
The main problem for controlling the
disease is that only a few strategies are eco-
nomically accessible, such as education, che-
motherapy, vector control using insecticides
or elimination of mosquito breeding sites,
and more recently, insecticide-impregnated
mosquito bed nets. It is certain that the best
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way to control the disease on a short-term
basis is investing more resources in cur-
rently available methods of control. It is well
documented that even small investments in
these areas are highly cost-effective. For
example, a single program of insecticide-
impregnated bed nets can reduce child mor-
tality in an entire African country (1). Larger
investments in malaria control programs
would have an enormous impact on most
endemic areas, reducing the number of cases
and casualties.
Mass vaccination against malaria is not
available, and it will not be feasible within
this century. Research in this field was once
considered as a priority that would lead to
the most powerful method of control and
prevention of the disease. However, in the
past ten years this concept has changed.
Malaria parasites display genetic mechanisms
to generate drug-resistant strains and to avoid
several immunological mechanisms of de-
fense. Accordingly, in areas where drugs or
eventually vaccines are used, parasites will
have to be constantly monitored for the pres-
ence of resistant mutant strains. In spite of
these limitations, mass vaccination is con-
sidered to be an approach that, in the future,
may complement other strategies such as
chemotherapy, vector control, etc., for pre-
vention and control of the disease.
Why has a malaria vaccine not been
developed?
Vaccines can prevent a number of infec-
tions by viruses and bacteria. The basis for
vaccine research and mass vaccination
against these microorganisms relies on cer-
tain facts. Viruses and bacteria can be easily
cultivated in vitro, and they have a relatively
simple life cycle. By generating large a-
mounts of microorganisms in vitro, it is pos-
sible to obtain antigenic fractions that can be
used for basic research, product develop-
ment and mass vaccination. The fact that
they have only a single form, a not so large
number of genes, and undergo limited mor-
phological and biochemical alterations dur-
ing their life cycle facilitates protective im-
mune responses. However, many exceptions
exist and a number of viral and bacterial
infections cannot be prevented by vaccines.
These basic characteristics of viruses and
bacteria are not shared by malaria parasites,
and some of the concepts of vaccination
generated by immunization against them can-
not be applied to most parasitic diseases. For
years, these limitations impaired the devel-
opment of a malaria vaccine and, at some
point, generated a very pessimistic view of
the problem. From a different perspective,
these roadblocks helped to create new con-
cepts in vaccination that will be required for
the development of an effective vaccine
against malaria and perhaps other complex
microbial infections.
Among the most critical factors that have
delayed the advances in this field is the
impossibility of generating large amounts of
parasites in culture. Up to now, sufficient
amounts of antigen can only be generated for
basic research, but not for product develop-
ment or mass vaccination. The second factor
is the complexity of the malaria parasite life
cycle. During their life cycle, malaria para-
sites undergo complex transformation gen-
erating several different forms that are mor-
phologically and antigenically distinct. There-
fore, individuals exposed to malaria have
contact with multiple forms of the parasite
expressing a variety of stage-specific pro-
teins. Another problem imposed by its com-
plex life cycle is the fact that distinct immu-
nological effector mechanisms are respon-
sible for eliminating different forms of the
parasite. Taken together, these aspects led to
the concept that an ideal malaria vaccine
would be a complex mixture of antigens
expressed at different stages of the parasite
life cycle produced by chemical synthesis or
recombinant DNA technology, or both. Due
to the polymorphism frequently detected in
several parasite antigens, a vaccine would
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have to be elaborated using immunogenic
regions of parasite antigens that are either
invariant or display a limited polymorphism.
Finally, an ideal vaccine will have to elicit
distinct immunological effector mechanisms
to attack the parasite at different stages of its
life cycle.
Based on these concepts, in the past 15
years, great advances have been made in
characterizing parasite antigens and the im-
munological effector mechanisms. The num-
ber of genes coding for antigenically rel-
evant proteins that have been cloned and
sequenced cannot find a parallel in any other
parasitic disease. This work can serve as the
basis for the development of a malaria vac-
cine. Nevertheless, it is important to high-
light that studies on the characterization of
antigens should continue since new protein
families have been only recently described
(2-4). Also, very few genes encoding P.
vivax antigens have been identified, and it
would be important to pursue studies in this
direction since this parasite co-exists with P.
falciparum on most continents where ma-
laria transmission occurs.
The advances in the description of the
immunological effector mechanisms which
lead to parasite elimination also provided
important insights on how an appropriate
anti-plasmodial immune response can be elic-
ited. Again, there is still more to understand
about the immunological effector mecha-
nisms in experimental models and humans.
Most relevant was the fact that multiple anti-
gens, expressed at distinct stages of the para-
site, were described as a target for the host
protective immunity, and therefore candi-
dates to be part of a subunit vaccine against
malaria (reviewed in Ref. 5).
Malaria parasite life cycle and
stage-specific immunological
mechanisms of parasite destruction
During a mosquito bite, sporozoites are
inoculated into the bloodstream where they
remain for only few minutes, being targets
for antibodies that react with a stage-specific
surface antigen, the circumsporozoite (CS)
protein (6). Sporozoites then invade hepato-
cytes and are no longer a target for anti-CS
antibodies. Inside hepatocytes, sporozoites
develop to schizonts and after a few days
they are released into the bloodstream as
merozoites. Liver schizonts express stage-
specific antigens as well as antigens that are
common to sporozoites and blood stages.
Because liver schizonts are intracellular, the
immunological effector mechanisms are only
mediated by T lymphocytes. CD8+ T lym-
phocytes specific for several antigens have
been described as the most powerful immu-
nological mechanism that inhibits the devel-
opment of liver stages of malaria. CD4+
lymphocytes also exert a certain inhibitory
effect on the development of this form of the
parasite (reviewed in Ref. 7).
When the tissue merozoites are released
into the circulation, they also become a tar-
get for antibody-mediated immunity. A vari-
ety of surface antigens have been described
as targets for antibodies that can inhibit eryth-
rocyte invasion in vitro (reviewed in Ref. 8).
Human protective antibodies also mediate
opsonization by blood monocytes (9). The
targets for antibodies that mediate opsoniza-
tion are not precisely known, and it is likely
that a number of them exist. Once merozoi-
tes invade red blood cells they transform into
trophozoites, subsequently to schizonts, and
finally are released as merozoites. It is cer-
tain that the intra-erythrocytic forms of ma-
laria are targets for the CD4+ T cell-mediated
immunity (10) and antibodies since some
parasitic antigens occur on the surface of
infected erythrocytes (2-4).
A small part of trophozoites transform
into gametocytes that undergo development
when ingested by susceptible mosquitoes.
Gametocytes express on their surface stage-
specific antigens which have been shown to
be targets for antibodies that impair parasite
development inside the mosquito, therefore
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blocking the cycle and transmission (11,12).
This type of immunity does not protect the
host, but by reducing the number of infected
mosquitoes and their parasitic load, it may
diminish malaria transmission. Finally, stage-
specific antigens expressed on the surface of
sexual forms of the parasite (zygotes and
ookinetes) can also be targets for transmis-
sion-blocking antibodies (13,14).
A schematic view of the parasite life
cycle and the different immunological mecha-
nisms that are capable of eliminating each
one of these forms is presented in Figure 1.
Synthetic peptides as candidates for
a malaria vaccine
Synthetic peptides are extremely attrac-
tive candidates for vaccines since they can
be produced on a large scale under extremely
well-controlled conditions. In fact, a syn-
thetic peptide coupled to a carrier antigen
was one of the first immunogens to be tested
in human trials against malaria (15). In the
past ten years, only a single major advance
has been made in this field that may have
some impact on the development of a ma-
laria vaccine. Branched peptides denomi-
nated multiple antigen peptides, or simply
MAPs, were developed (Figure 2), and
proved to be more immunogenic than linear
peptides (16). Mice immunized with a MAP
containing a B cell epitope of the CS protein
coupled to a CD4+ T cell epitope produced
very high antibody titers that mediate protec-
tive immunity against challenge with sporo-
zoites of two distinct rodent malarias (16,
17). Details on the properties and advan-
tages of these MAPs have been recently
reviewed in reference 18. These optimistic
results have justified human trials scheduled
to start soon.
The “vaccine” developed by Dr. Manuel
Patarroyo, a synthetic peptide denominated
SPf66, experienced great success after ini-
tial immunization trials in monkeys and hu-
mans and was named “the first malaria vac-
cine” (19). This success sold a lot of hope to
certain international organizations and news-
papers. However, these results could not be
duplicated in other trials on monkeys (20) or
humans performed later in different parts of
the world (21-23). The immunological basis
for protection observed during the first group
of trials was never elucidated. It is unknown
whether SPf66 elicits a certain degree of
protective immunity mediated by antibodies
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or T cells, or both, as discussed in reference
24.
The concept of using synthetic peptides
as an ideal vaccine against malaria has not
advanced as expected in the past years. Other
problems of using synthetic peptides are as
follows. Peptides are relatively short. Recent
advances in peptide synthesis have permit-
ted the generation of linear peptides of more
than 100 amino acids (25). This amount of
antigenic information is still very limited if
one considers that an ideal malaria vaccine
would have to be the product of several
genes. It seems unlikely that it can be ob-
tained by chemical synthesis only. Also, cor-
rect peptide folding can be rarely achieved
and most conformational epitopes may not
be generated using synthetic peptides.
Recent advances in the generation
of recombinant proteins and their
impact on the development of a
malaria vaccine
In contrast to synthetic peptides, protein
production using recombinant DNA tech-
nology has advanced very fast in the past 12
years. In the mid 1980’s, only very limited
quantities of proteins could be generated in
few prokaryotic expression systems. Today,
a variety of expression systems are available
to produce recombinant proteins, and their
number continues to increase every year.
The expression of foreign proteins can now
be obtained in viruses, bacteria, and in lower
and higher eukaryotic systems. They became
a very important tool for basic research,
product development and even mass pro-
duction of vaccines such as hepatitis vac-
cine.
Different expression vectors can provide
solutions for most of the initial problems of
protein expression such as inappropriate pro-
tein folding, low protein yields and complex
purification processes. By choosing the cor-
rect vector, it is now possible to select the
microorganism that provides the best protein
folding, or produces the largest amount of
protein or requires the easiest purification
schedules. A second relevant point is the fact
that these distinct vectors made possible the
selection of the vehicle that elicits the type of
immune response required for protection.
Recombinant proteins
CS protein
The CS protein is the most abundant
protein that covers the entire sporozoite sur-
face and is also expressed by malaria liver
stages. Its biological function has recently
been elucidated by deletion of the CS gene in
the rodent malaria parasite P. berghei.
“Knockout” of the CS gene generates a para-
site strain which evolves normally as blood
stages; however, sporozoites do not develop
inside mosquito oocysts (26). This result
strongly suggests that the CS protein is struc-
turally required for generation of sporozoites.
Other studies have also implicated this pro-
tein as a mediator of sporozoite binding and
invasion of hepatocytes in mammalian hosts
(27).
The structure of this protein has been
thoroughly described (6). Briefly, the CS
protein of all malaria species contains a cen-
tral domain consisting of several amino acid
repetitions. The amino acid sequence that
composes each repetition is completely dif-
ferent among Plasmodium species. In P. fal-
ciparum, the only strain variability described
so far is related to the number of the (NANP)
X3 repetitions. In contrast, P. vivax isolates
display an enormous variation in the se-
quence of these repetitions (28) and, there-
fore, P. vivax CS protein is not likely to be a
candidate for a malaria vaccine.
The amino acid repetitions of the CS
protein are known as targets for antibodies
that can provide sterile immunity for exper-
imental animals. Other regions of the CS
protein (N- and C-terminal) contain epitopes
that are recognized by CD4+ or CD8+ T cells
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from several different MHC haplotypes of
humans and rodents (reviewed in Ref. 7). It
is also well established that T cells specific
for epitopes of the CS protein confer protec-
tive immunity against liver stages of rodent
malaria parasites. Therefore, the CS protein
is a target for protective antibodies that block
sporozoite invasion in hepatocytes and T
cells that inhibit the development of liver
stages of malaria.
Recombinant proteins produced in E. coli
or yeast have been widely used to study the
induction of protective immunity using the
CS protein. In fact, an E. coli-derived recom-
binant protein representing the repetitive
domain of the P. falciparum CS protein was
one of the first immunogens to be used in a
human vaccination trial (29). This study dem-
onstrated the safety and immunogenicity of
this recombinant protein for human immuni-
zation. However, protection was relatively
poor and only one out of six immunized
volunteers was protected after exposure to
infected mosquitoes. Although negative,
these results were important since they sug-
gested that, if improved, immunization with
a recombinant CS protein could be of great
use to elicit sterile protective immunity
against malaria. Also very important was the
fact that this and other bacterial recombinant
proteins were extremely useful for testing
new adjuvants for improvement of human
antibody and cellular immune response (30).
In spite of these efforts, in many subsequent
studies E. coli-derived recombinant CS pro-
teins could not improve sterile immunity
beyond 2 of 11 volunteers challenged with
P. falciparum sporozoites (31).
More recently, human trials were per-
formed using a recombinant protein based
on the sequence of the P. falciparum CS
protein produced in yeast. This recombinant
protein consisted of 189 amino acids (from
207 to 395) of the P. falciparum CS protein
fused to hepatitis B surface antigen (S anti-
gen). This fusion protein was denominated
RTS and its gene was simultaneously ex-
pressed in Saccharomyces cerevisiae with
the gene encoding the S antigen (32,33). The
protein particle resulting from the expres-
sion of the RTS and S gene was denominated
RTS,S (Figure 3). The S antigen is an inte-
gral membrane protein and the major anti-
gen of hepatitis B virus. This protein is known
to be highly antigenic for humans and it is
currently used for mass vaccination in many
countries.
Initial studies were performed by immu-
nizing groups of volunteers with RTS,S emul-
sified in alum only, or alum plus 3-deacylated
monophosphoryl lipid A (MPL) derived from
Salmonella minnesota lipopolysaccharide.
The second group of individuals had a con-
sistently higher antibody titer to the repeat
region of the CS protein and after challenge
with sporozoites, 2 out of 8 volunteers were
protected against malaria (32). In contrast,
none of the individuals immunized with
RTS,S in alum were protected. This study
also demonstrated that an adjuvant formula-
tion could be of great relevance for the in-
duction of protective immunity against ma-
laria in humans.
A recently published study was designed
to evaluate three different adjuvant combi-
CS Protein
(aa 207-395)
HBsAg
COOHNH2
RTS
S
HBsAg
Purification
Yeast
RTS S
B
AFigure 3 - Schematic representa-
tion of RTS,S particles. A, RTS
and S proteins; B, RTS, S par-
ticles. HBsAg, Hepatitis B sur-
face antigen (S antigen).
323
Braz J Med Biol Res 31(3) 1998
Malaria vaccine
nations using as antigen the protein RTS,S.
The volunteers were divided into three groups
which were immunized with RTS,S in three
distinct adjuvant preparations. The first group
was immunized with RTS,S in alum plus
MPL. The second group was injected with
RTS,S in an oil-in-water emulsion. The third
group was immunized with this emulsion
plus MPL and QS21 (saponin). The antibody
titers against sporozoites or the repeat region
of the CS protein were significantly higher in
individuals immunized with the last two
preparations. After challenge with sporo-
zoites, striking results were observed. While
6 of 7 individuals (85.7%) were completely
protected against malaria in group 3, only
28.6% of the individuals were protected in
group 2 and 12.5% in group 1 (33). The
results imply that the correct adjuvant for-
mulation is crucial to elicit a high degree of
protective immunity. The precise mechanism
of protection is unknown. Groups 2 and 3
had antibody titers that were not significant-
ly different. Therefore, if protective immu-
nity is dependent on antibodies, it is likely
that the avidity or fine epitope specificity of
these immunoglobulins is more important
than their serum concentration. The basis of
protective immunity will require detailed a-
nalysis of the humoral and cellular immune
response to the CS protein. Based on this
very promising result, field trials in endemic
areas of malaria are expected soon.
Merozoite surface protein 1
Among the proteins of the blood stages
of Plasmodium, the merozoite surface pro-
tein 1 (MSP1) has been the most intensively
studied as a potential target for protective
immunity. This protein is synthesized as a
precursor of large molecular mass (180-230
kDa) during schizogony and is later pro-
cessed to some of the major merozoite sur-
face proteins (reviewed in Ref. 34). During
the invasion process, proteolytic cleavage
releases most of the molecule from the mero-
zoite surface and only a 19-kDa fragment of
the C-terminal region (MSP119) is carried
into the invaded red cells (35,36). The bio-
logical importance of MSP1 for parasite sur-
vival is unknown, but it is well established
that antibodies that recognize its C-terminal
region inhibit merozoite invasion in vitro
(37,38), and confer passive immunity on
naive mice (39). Initial studies of immuniza-
tion with MSP1 purified from blood stages
showed that rodents or monkeys could be
successfully vaccinated against P. yoelii or
P. falciparum infection, respectively (40,41).
The potential of this molecule for vac-
cine development motivated studies aimed
at the generation of recombinant proteins
containing portions of MSP1. Several re-
combinant proteins based on the MSP1 se-
quence of different Plasmodium species were
used to immunize rodents and monkeys. A
certain degree of protective immunity could
be achieved in monkeys after immunization
with recombinant proteins based on the se-
quence of the N-terminal region of MSP1
(denominated PL190) fused to a T cell epi-
tope (42).
However, it was not until recently that
remarkable protective immunity could be
elicited in experimental models by immuni-
zation with a few such recombinant proteins.
These studies used recombinant proteins
based on the sequence of the C-terminal
region (42 or 19 kDa) of MSP1 of distinct
Plasmodium species (Figure 4). This region
of the molecule, particularly the MSP119, is
considered to be of limited polymorphism
Figure 4 - Schematic representa-
tion of merozoite surface pro-
tein 1 of Plasmodium sp.
Polymorphic
COOHNH2
19 kDa
Limited polymorphism
(P. falciparum)
Conserved (P. vivax)
324
Braz J Med Biol Res 31(3) 1998
I.S. Soares and M.M. Rodrigues
since only few amino acid substitutions are
observed among different strains of P. falci-
parum. In the case of P. vivax MSP119, the
variability is very restricted and only a single
amino acid substitution has been reported
(43). Also relevant is the fact that MSP119
contains epitopes that are recognized by an-
tibodies and T cells of individuals naturally
exposed to P. falciparum and P. vivax ma-
laria (44,45).
Immunization of mice with an E. coli-
derived recombinant protein containing
MSP119 resulted in very effective protection
upon lethal challenge with P. yoelii blood
stages (46,47). The induction of protective
immunity requires epidermal growth factor-
like motifs present in MSP119 (48) and is
mediated predominantly by antibodies (49).
These results, therefore, suggest that epi-
topes in MSP119 are targets for the protective
antibodies. It will be important to elucidate
the mechanism used by specific antibodies
to inhibit the development of blood stages
since they may have an impact on the design-
ing of a vaccine against malaria blood stages.
Using recombinant proteins based on the
sequence of the P. falciparum MSP1 C-
terminal region, three independent trials were
performed using Aotus monkeys. A sum-
mary of these trials is presented in Table 1.
In the first trial, animals were immunized
with an E. coli-derived GST-MSP142 fusion
protein or a yeast-derived recombinant
MSP119 (50). The results showed that both
Aotus nancymai monkeys immunized with
MSP119 in Freund’s adjuvant recovered from
blood stage infection without requiring treat-
ment. In contrast, all three control animals
required treatment by day 17 and only one
out of three animals immunized with GST-
MSP142 was partially protected. Two other
monkeys (Aotus vociferans) were immunized
with MSP119 in Freund’s adjuvant and only
one had a prolonged pre-patent period.
In the second trial, three Aotus lemurinus
griseinmembra monkeys were immunized with
a baculovirus-derived recombinant protein con-
taining a 42-kDa fragment of the C-terminal
region of Pf MSP1 emulsified in Freund’s ad-
juvant (51). These animals developed very
high titers of antibodies to the native protein as
well as to the recombinant proteins represent-
ing MSP142 and MSP119. After challenge with
blood stages, two of these monkeys never
developed parasitemia and the third animal
had a significant delay in the pre-patent period
when compared to control animals immunized
with adjuvant only.
The third trial was performed by immu-
nizing Aotus nancymai monkeys with an E.
coli-derived GST-MSP119 fusion protein. The
adjuvant used was either alum or liposomes.
The antibody titers were far lower than the
titers observed in the other two immuniza-
tion trials. Upon challenge with blood stages
no protective immunity was observed in ei-
ther group immunized with GST-MSP119
(52).
Table 1 - Summary of vaccination experiments in monkeys with recombinant proteins derived from the C-
terminal region of Plasmodium falciparum MSP1.
Recombinant Source Adjuvant Aotus Number of animals Ref.
antigen species
Vaccinated Delayed pre- Complete
patent period protection
GST-MSP142 Bacterial Freund’s A. nancymai 3 1 None 50
MSP19 Yeast Freund’s A. nancymai 2 2 2 50
MSP19 Yeast Freund’s A. vociferans 2 1 0 50
MSP42 Baculovirus Freund’s A. lem. gris. 3 3 2 51
GST-MSP119 Bacterial Alum A. nancymai 3 None None 52
GST-MSP119 Bacterial Liposomes A. nancymai 3 None None 52
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The results of these trials strongly sug-
gest that immunization with the C-terminal
region of MSP1 can elicit protective immu-
nity against malaria in non-human primates.
Also, they suggest that the immune response
to MSP119 of other species can be protective.
In fact, immunization of Saimiri monkeys
with a baculovirus-derived recombinant pro-
tein of PvMSP119 elicited strong protective
immunity to P. vivax blood stages, signifi-
cantly reducing the parasitemia in this ex-
perimental model (Dr. John Barnwell, per-
sonal communication). Unfortunately, so far,
protective immunity could only be gener-
ated using a strong adjuvant such as
Freund’s, which is not allowed for human
use. As was the case for the immunization
with the CS protein, the adjuvant formula-
tion seems to play a key role in the induction
of protective immunity to malaria. This pos-
sibility is also supported by experiments in
the mouse model showing that the adjuvant,
the host genotype and the fine epitope speci-
ficity of antibodies significantly influence
the protective immunity elicited by immuni-
zation with the C-terminal region of MSP1.
Serine repeat antigen
Serine repeat antigen (SERA) is a 110-
kDa protein produced in large amounts by
trophozoite-schizont blood stages of P. fal-
ciparum and P. vivax (53). The deduced
amino acid sequence of SERA obtained from
different isolates of P. falciparum suggests
that most of the protein is highly conserved,
except for the region flanking the serine
repeats. Two recombinant proteins were gen-
erated in S. cerevisiae. SERA 1 and SERA N
represented amino acids 24 to 285 and 24 to
506, respectively. Immunization of Panama-
nian Aotus monkeys with either recombi-
nant protein emulsified in Freund’s adjuvant
elicited strong protective immunity capable
of reducing blood stage parasitemia by at
least 10-fold. Subsequent studies were car-
ried out using only the recombinant SERA 1
with adjuvants suitable for human use. The
overall results from these trials showed that
9 of 14 monkeys immunized with SERA 1 in
the presence of Freund’s adjuvant and 7 of
11 monkeys immunized with SERA 1 and
MF75.2 adjuvant did not develop detectable
parasitemia after challenge with blood stages
of P. falciparum. However, several of the
immunized and protected monkeys devel-
oped recurring low-grade infection after a
prolonged period. The basis for the protec-
tive immunity observed in these animals has
not been thoroughly studied, but sera from
the immunized animals displayed antibodies
that inhibited parasite growth in vitro (53).
Another successful attempt to use re-
combinant proteins was made by immuniza-
tion of animals with yeast-derived recombi-
nant proteins based on the sequence of the
zygote and ookinete stage-specific antigens
Pf25 and Pf 28. The monkeys and mice im-
munized with these recombinant proteins
developed antibodies that blocked develop-
ment of oocysts, providing strong transmis-
sion-blocking immunity (13,14).
Several other antigens are being actively
studied as potential candidates to be part of a
malaria vaccine. These antigens have been
produced by recombinant DNA technology.
In most cases, few data are available to date
on their ability to elicit protective immunity
in experimental models.
Recombinant viruses and other
live vectors
Recombinant live viruses expressing for-
eign antigens have the potential to be used as
delivery systems designed to elicit protec-
tive immune responses against several mi-
crobial infections. Recombinant viruses can
be easily produced on a large scale and, in
many cases, the non-recombinant form of
these viruses has been successfully used for
mass vaccination of humans. As the first
virus that could be genetically manipulated,
vaccinia virus was used in most studies per-
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formed so far. However, recent develop-
ments in the field of genetic manipulation of
viral DNA and RNA made possible the utili-
zation of a number of other viruses such as
influenza, adenovirus, sinbis, and pseudora-
bies virus, among others.
The vast majority of studies were per-
formed using different recombinant viruses
expressing the CS protein. The fact that its B
cell epitope (54) and CD8+ T cell epitope
(55,56) have been mapped allowed the gen-
eration of recombinant viruses containing
either or both epitopes. These studies were
performed on mice and unequivocally
showed that a number of recombinant vi-
ruses can be used to elicit protective immu-
nity against sporozoites and liver stages of
malaria.
Several important concepts emerged from
these studies. First, protective immunity elic-
ited by distinct recombinant viruses varies in
magnitude. Several different recombinant
viruses containing the entire P. yoelii pro-
tein, or its B cell or CD8+ T cell epitope were
compared in terms of their ability to elicit
protective immunity against pre-erythrocyt-
ic stages of malaria. Individually, immuniza-
tion of mice with a recombinant adenovirus
expressing the entire CS protein of P. yoelii
produced the highest degree of immunity to
a challenge with sporozoites (Table 2; 57).
On the other hand, in mice immunized with
a recombinant influenza virus containing only
the CD8+ T cell epitope of the CS protein, no
inhibition of liver stage development was
observed (58). Immunization with either vi-
rus induced an easily detectable CD8+ T cell-
mediated immune response, and protective
immunity mediated by recombinant aden-
ovirus was mainly mediated by this lympho-
cyte subpopulation (57). To our knowledge,
up to now, experimental malaria has been
the model with the largest number of recom-
binant viruses compared for their ability to
Table 2 - Summary of experiments using recombinant viruses to elicit protective immunity against pre-
erythrocytic stages of Plasmodium yoelii.
Recombinant Antigen Number % of liver Complete Mechanism of Ref.
expressed of doses stage protection protection
inhibition
Adenovirus Entire CS protein 1 ~94% 40% Mainly CD8+ T cells 57
Influenza CD8+ T cell epitope 2 >95% 60% CD8+ T cells 58,59
+
Vaccinia Entire CS protein
Influenza CD8+ T cell epitope + 4 >95% 78-81% Antibodies and 59
+ B cell epitope CD8+ T cells
Vaccinia Entire CS protein
Influenza CD8+/B cell epitopes 3 ~85% 50% Antibodies and 59
CD8+ T cells
Vaccinia Entire CS protein 2 ~55% None CD8+ T cells 58,59
Vaccinia CD8+ T cell epitope 2 ~75% None CD8+ T cells 58,59
Influenza B cell epitope 3 ~85% None Antibodies 59
Influenza CD8+ T cell epitope 2 <15% None None 58
Pseudorabies Entire CS protein 2 Unknown None None 59
Vaccinia Entire CS protein 2 <15% None None 58
+
Influenza CD8+ T cell epitope
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elicit protective immunity. The results ob-
tained with this system emphasize the im-
portance of detailed comparative studies to
determine the best recombinant virus ca-
pable of inducing the highest degree of pro-
tective immunity to a certain pathogen.
Distinct recombinant viruses generate
protective immunity by different effector
mechanisms reacting to different stages of
the parasite. Immunization with recombi-
nant vaccinia and adenovirus expressing the
CS protein elicits protective immunity that is
mainly mediated by CD8+ T cells against
liver stages (57,58). In these two models
depletion of CD8+ T cells, before challenge
with parasites, completely reversed protec-
tive immunity. Immunization with a recom-
binant vaccinia virus expressing only the
CD8+ T cell epitope was as efficient as im-
munization with a virus containing the full-
length CS gene (59). In contrast, protective
immunity induced by immunization with a
recombinant influenza virus could only be
obtained using a recombinant virus express-
ing the CS B cell epitope that is present on
the surface of sporozoites (59).
A third concept emerging from these stud-
ies was that sequential immunization with
two distinct live viruses expressing the same
CD8+ T cell epitope has the potential to
increase significantly protective immunity
mediated by CD8+ T cells against liver stages
(58,59). Initial results demonstrated that prim-
ing of mice with a recombinant influenza
virus followed by a booster injection with a
recombinant vaccinia virus, both expressing
the CD8+ T cell epitope, elicited a high de-
gree of protective immunity against a sporo-
zoite challenge (59). Similar protective im-
munity could not be achieved with two doses
of either influenza or vaccinia virus. This
unexpected observation was explained by
the fact that mice immunized with these two
different carrier viruses have a frequency of
malaria peptide-specific CD8+ T cells 20-30
times higher than that of animals immunized
twice with recombinant vaccinia or influ-
enza virus (60). The frequency of malaria-
specific CD8+ T cells depends on the order
of immunization with these two viruses. In
mice primed with recombinant vaccinia vi-
rus followed by a booster injection with
recombinant influenza virus, the frequency
of CD8+ T cells was 10 times lower (60). No
protective immunity could be detected in
this case (59). The reasons for these differ-
ences remain unknown, but it is clear that the
immune response mediated by CD8+ T cells
can be greatly increased by certain combina-
tions of recombinant viruses that can be used
to increase protective immunity against liver
stages of malaria.
Immunization of experimental animals
with a recombinant virus expressing the zy-
gote stage-specific antigen Pf 25 also gener-
ated immunity against malaria. The sera from
monkeys and mice immunized with this re-
combinant virus had antibodies that could
significantly inhibit the development of oo-
cysts, providing strong transmission-block-
ing immunity (61).
Several improvements can be made since
DNA viruses, such as vaccinia or adenovi-
rus, may carry in their genome significantly
higher amounts of genetic information. This
allows the expression of several relevant
epitopes of different plasmodial proteins in-
stead of a single one. In fact, a recombinant
vaccinia virus has been recently developed
expressing 7 genes of distinct stages of Plas-
modium falciparum (62).
A second area for potential advances in
this field is the improvement of the immuno-
genicity of these recombinant viruses ob-
tained by expressing immuno-stimulatory cy-
tokines, or co-stimulatory receptors. In par-
allel to the increase in the immunogenicity of
these viruses, their virulence can be reduced
by the generation of attenuated viral strains,
important for the use in children and preg-
nant women. A variety of attenuated strains
of these viruses are being developed today
mainly by genetic manipulation, and many
of the viruses used in the studies described
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above were either attenuated (vaccinia and
influenza) or replication defective (adenovi-
rus) strains.
A human trial has been scheduled using a
recombinant vaccinia virus expressing 7 genes
of distinct stages of Plasmodium falciparum
(62). However, this trial should be viewed
with caution because there is no evidence that
immunization with this virus elicits protective
immunity in non-human primates. A second
major concern in the use of recombinant vi-
ruses for human trials is the fact that no evi-
dence is available that a recombinant virus
generates protective immunity against blood
stages of malaria. As mentioned above, an
ideal vaccine carrier should elicit protective
immunity to different stages of malaria para-
sites. This problem could be solved eventually
by a simultaneous immunization with a mix-
ture of blood stage recombinant antigens in
adjuvant.
A recombinant Salmonella vector ex-
pressing the CS protein was also proposed as
a possible candidate vaccine against ma-
laria. Initial studies in rodent malaria in-
duced by P. berghei sporozoites suggested
that this vehicle could elicit protective im-
munity against pre-erythrocytic stages of ma-
laria (63). A subsequent study using a more
virulent strain of rodent malaria (P. yoelii)
was not successful. Based on the initial re-
sults obtained with P. berghei, a recombi-
nant Salmonella vector expressing the P.
falciparum CS protein was developed but its
first human trial was disappointing, with
most individuals failing to respond (64).
DNA vaccination
Plasmid DNA is the most recently devel-
oped delivery system designed to elicit an
immune response to microorganisms. This
type of immunization has the potential to
revolutionize the field of vaccination since,
for the first time, the antigen formulation
does not contain any type of protein. It con-
sists of an expression vector (plasmid DNA)
in which the gene of a microbial antigen is
placed under the control of a strong pro-
moter for expression in eukaryotic cells. Once
injected into animals, the plasmid transfects
cells and drives the expression of the foreign
gene in vivo. In this system, the antigenic
protein is produced in situ by the transfected
cell for long periods of time. This approach
is relatively simple when compared to other
expression systems, as confirmed with a num-
ber of microbial genes including Plasmo-
dium genes (reviewed in Ref. 65).
The initial study performed in malaria
used an expression vector containing the
entire CS gene of P. yoelii. Immunization
with this plasmid DNA resulted in a strong
immune response mediated by antibodies
and CD8+ T cells, and provided a high de-
gree of protective immunity in BALB/c mice
against a challenge with sporozoites depend-
ent on CD8+ T cells (66). This protective
immunity was genetically restricted and only
BALB/c mice were effectively protected.
Immunization with a second plasmid carry-
ing the gene of the Py17Hep antigen was
also shown to generate a significant degree
of protective immunity against a challenge
with P. yoelii sporozoites. Similarly, this
protective immunity was mediated by CD8+
T cells and was genetically restricted (67). In
order to circumvent this strong genetic re-
striction, several mouse strains were immu-
nized with both plasmids. This type of im-
munization led to a high level of protective
immunity in 4 out of 5 mouse strains (68).
This experiment highlights the importance
of immunization with multiple malaria anti-
gens to elicit a high degree of protective
immunity in individuals with distinct genetic
backgrounds. Based on these results, human
vaccination trials are scheduled to be initi-
ated as early as in 1997.
The immunogenicity of this type of vec-
tor can be further enhanced by co-immuni-
zation with plasmids containing genes for
cytokines or co-stimulatory molecules of the
immune system (69).
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Conclusions
The study of malaria is a field that has
evolved very fast over the last ten years.
Based on the results obtained in studies di-
rected towards the development of a malaria
vaccine, we now know more about the para-
site itself, malaria pathogenesis and immuni-
ty. These studies have also generated basic
knowledge in a variety of fields such as
parasitology, molecular genetics, biochem-
istry, and immunology. The fact that a prod-
uct for mass vaccination has not been devel-
oped during this period is a consequence of
numerous roadblocks. Some of them, such
as antigenic polymorphism and antigenic
variation, were predictable, based on studies
with other microorganisms. Others, such as
the stage specificity of antigen expression
and immunological mechanisms of protec-
tion, were found during the course of these
studies. Yet, in spite of them, a significant
advance was made in this field. Today, sev-
eral epitopes of limited polymorphism have
been described and protective immunity can
be generated by active immunization. Immu-
nization was often performed with a single
antigen which generated stage-specific pro-
tection. Therefore, if several antigens can be
assembled in the same vaccine, they can
provide higher levels of protection by attack-
ing the parasite at different points of the life
cycle. This can be accomplished in the near
future provided that it is demonstrated that
immunity to one epitope does not interfere
with immunity to another. Unfortunately, no
one can predict if and when a product will be
available for mass vaccination. During this
time, it is a reasonable understanding that
considerable investments should be made in
programs for education, vector control, in-
secticide-impregnated bed nets and chemo-
therapy.
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